ZA
TBPH icon

Zazove Associates’s Theravance Biopharma TBPH Stock Holding History

Zazove Associates’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-59,599
Closed -$540K – 174
2022
Q2 		$540K Hold
59,599
– – 0.05% 120
2022
Q1 		$570K Buy
+59,599
New +$584K 0.05% 125
2021
Q3 		$678K Buy
+91,669
New +$1.03M 0.06% 123

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zazove Associates's TBPH Position: Q3 2022 in Review

Zazove Associates sold out of Theravance Biopharma (TBPH) in Q3 2022, closing a stake of 59,599 shares — an estimated $540K sold.

Zazove Associates first reported a position in TBPH in Q3 2021 and held it in 3 quarters. The position peaked at $678K in Q3 2021. 123 funds tracked by Wall St. Rank hold TBPH as of Q3 2022.

  • Zazove Associates reported no remaining Theravance Biopharma position as of Q3 2022 after selling out during the quarter.
  • Zazove Associates sold 59,599 Theravance Biopharma shares in Q3 2022, an estimated $540K.
  • Zazove Associates first reported a position in Theravance Biopharma in Q3 2021 and held it in 3 quarters.
  • Zazove Associates's Theravance Biopharma position peaked at $678K in Q3 2021.
  • 123 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2022.

Based on Zazove Associates's 13F filing for Q3 2022, filed 24 Oct 2022.